Classes
DEA Class; Rx
Common Brand Names; Mobic, Vivlodex, Anjeso, Qmiiz
NSAIDs
Description
Oral and parenteral nonsteroidal anti-inflammatory drug (NSAID)
Used for osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis and moderate or severe pain alone or in combination with other non-NSAID analgesics
Associated with increased risk of serious cardiovascular or gastrointestinal (GI) tract adverse effects
Indications
Contraindications
Known hypersensitivity (eg, anaphylactic or serious skin reactions)
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
Perioperative pain management in the setting of coronary artery bypass graft (CABG) surgery
Anjeso: Moderate-to-severe renal insufficiency in patients at risk for renal failure owing to volume depletion
Qmiiz: Phenylketonuria
Adverse Effects
>10%
Borderline elevations of one or more LFTs (<15%)
1-10%
Abdominal pain
Anorexia
Diarrhea
Nausea
Pyrosis
Gastritis
Flatulence
Constipation
Steatorrhea
Upper GI ulcers, gross bleeding/perforation (1% of patients treated for 3-6 mth and 2-4% of those treated for 1 yo)
Warnings
Increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal
Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs
The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease; however, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events
Increased CV thrombotic risk has been observed most consistently at higher doses
Minimize potential risk by using lowest effective dose for the shortest duration possibleCABG
Pregnancy and Lactation
Pregnancy; Data from observational studies regarding potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive
Lactation: Human data are not available on whether meloxicam is present in human milk, or on the effects on breastfed infants, or on milk production
Maximum Dosage
15 mg/day PO for tablets, including oral disintegrating tablets, and suspension; 10 mg/day PO for capsules; 30 mg/day IV.
15 mg/day PO for tablets, including oral disintegrating tablets, and suspension; 10 mg/day PO for capsules; 30 mg/day IV.
0.125 mg/kg/day (Max: 7.5 mg/day) PO for tablets, including oral disintegrating tablets, and suspension; safety and efficacy have not been established for capsules or IV injection.
2 to 12 years: 0.125 mg/kg/day (Max: 7.5 mg/day) PO for tablets, including oral disintegrating tablets, and suspension; safety and efficacy have not been established for capsules or IV injection.
1 year: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
tablet (Mobic)
7.5mg
15mg
tablet, oral distintegrating (Qmiiz)
7.5mg
15mg
capsule (Vivlodex)
5mg
10mg
injection, IV aqueous dispersion (Anjeso)
30mg/mL single-dose vial
